

MicroRNA hsa-miR-1301-3p Regulates Human *ADH6*, *ALDH5A1* and *ALDH8A1* in the Ethanol-Acetaldehyde-Acetate Metabolic Pathway[§]

Xubing Wang,¹ Yanjie Zhao,¹ Jiao Luo, Lin Xu, Xinmei Li, Yuan Jin, Chuanhai Li, Meiyao Feng, Ying Wang, Jing Chen, Yufei Hou, Qianwen Zhao, Jinquan Zhao, Baitang Ning, Yuxin Zheng, and Dianke Yu

School of Public Health, Qingdao University, Qingdao, China (X.W., Ya.Z., J.L., L.X., X.L., Y.J., C.L., M.F., Y.W., J.C., Y.H., Q.Z., J.Z., Yu.Z., D.Y.) and National Center for Toxicological Research, US Food and Drug Administration, Jefferson, Arkansas (B.N.)

Received February 4, 2020; accepted May 27, 2020

ABSTRACT

Alcohol dehydrogenases (ADHs) and aldehyde dehydrogenases (ALDHs) are vital enzymes involved in the metabolism of a variety of alcohols. Differences in the expression and enzymatic activity of human ADHs and ALDHs correlate with individual variability in metabolizing alcohols and drugs and in the susceptibility to alcoholic liver disease. MicroRNAs (miRNAs) function as epigenetic modulators to regulate the expression of drug-metabolizing enzymes. To characterize miRNAs that target ADHs and ALDHs in human liver cells, we carried out a systematic bioinformatics analysis to analyze free energies of the interaction between miRNAs and their cognate sequences in *ADH* and *ALDH* transcripts and then calculated expression correlations between miRNAs and their targeting *ADH* and *ALDH* genes using a public data base. Candidate miRNAs were selected to evaluate bioinformatic predictions using a series of biochemical assays. Our results showed that 11 miRNAs have

the potential to modulate the expression of two *ADH* and seven *ALDH* genes in the human liver. We found that hsa-miR-1301-3p suppressed the expression of *ADH6*, *ALDH5A1*, and *ALDH8A1* in liver cells and blocked their induction by ethanol. In summary, our results revealed that hsa-miR-1301-3p plays an important role in ethanol metabolism by regulating *ADH* and *ALDH* gene expression.

SIGNIFICANCE STATEMENT

Systematic bioinformatics analysis showed that 11 microRNAs might play regulatory roles in the expression of two alcohol dehydrogenase (*ADH*) and seven aldehyde dehydrogenase (*ALDH*) genes in the human liver. Experimental evidences proved that hsa-miR-1301-3p suppressed the expression of *ADH6*, *ALDH5A1*, and *ALDH8A1* in liver cells and decreased their inducibility by ethanol.

Introduction

Upon consumption, 80% of ethanol is absorbed in the upper small intestine and then transported to other organs. The liver is the primary site of ethanol metabolism. Excessive ethanol consumption is a common cause of liver injury and alcoholic liver disease (ALD) that encompasses liver manifestations, including fatty liver, fibrosis, cirrhosis, or even hepatocellular carcinoma (Adachi and Brenner, 2005; Tilg and Day, 2007). In

China, the prevalence of ALD has increased considerably in recent years, which is correlated with an increase in alcohol consumption (Heo et al., 2019).

The major two-step oxidative metabolic pathway for ethanol begins with its oxidation to acetaldehyde with further oxidation to produce acetic acid (Dinis-Oliveira, 2016). The oxidation of ethanol to acetaldehyde is catalyzed by alcohol dehydrogenases (ADHs) and CYP2E1; this constitutes the rate-limiting step of ethanol metabolism. Subsequently, acetaldehyde is further oxidized to acetic acid by aldehyde dehydrogenases (ALDHs) using NAD as the cofactor, which is followed by elimination of the acetic acid end product through urine.

Obvious individual variability in ethanol metabolism is noted among humans, and this is partially attributed to differences in genetic background, age, sex, and health status (Liangpunsakul et al., 2016). For example, studies showed that functional genetic variants in *ADH* and *ALDH* genes affected the activities or the expression levels of ethanol-

Disclaimer: The information in this paper is not an official guidance or policy statement of the US Food and Drug Administration (FDA). No official support or endorsement by the US FDA is intended or should be inferred.

This study was supported and funded by the National Key Research and Development Program of China (SQ2017YFC1600201), National Natural Science Foundation of China (91743113, 81973075, and 81903354), and Young Taishan Scholars Program of Shandong Province (tsqn201812046).

¹X.W. and Y.Z. contributed equally to this work.

<https://doi.org/10.1124/mol.120.119693>.

[§] This article has supplemental material available at molpharm.aspetjournals.org.

ABBREVIATIONS: ADH, alcohol dehydrogenase; ALD, alcoholic liver disease; ALDH, aldehyde dehydrogenase; -F, forward; FREMSA, fluorescent-based RNA electrophoretic mobility shift assay; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; miRNA, microRNA; MRE, miRNA response element; Mut, mutant; NC, negative control; -R, reverse; RT-PCR, real-time polymerase chain reaction; TCGA, The Cancer Genome Atlas; UTR, untranslated region.

metabolizing enzymes, thus varying the catabolic rate of ethanol (Birley et al., 2009; Hartwell and Kranzler, 2019).

ADH and ALDH proteins represent two distinct families of enzymes. Specifically, the ADH family consists of multiple isozymes and allozymes that are divided into five (I-V) classes (Cederbaum, 2012), whereas the ALDH superfamily includes 19 functionally related family members (Vasiliou and Nebert, 2005). In addition to the primary function of ADHs and ALDHs members (especially ADHs and ALDH2) in ethanol metabolism, ADHs and ALDHs are also involved in metabolizing a large spectrum of biologically important alcohols and aldehydes, including drugs (Jelski and Szmitskowski, 2008).

The complexity of regulatory mechanisms underlying ethanol metabolism is not fully understood. Epigenetic regulatory mechanisms, including DNA methylation, non-coding RNAs, and histone modification, provide novel genotype-independent mechanisms to modulate gene expression, contributing to individual variability in the metabolism and toxicity of ethanol and other chemicals (Rodenhiser and Mann, 2006; Moss and Wallrath, 2007; Davison et al., 2009; Meng et al., 2012; McDaniel et al., 2014). The microRNAs (miRNAs), a class of noncoding single-stranded RNA molecules typically about 22 nucleotides in length, are well-recognized as important epigenetic mediators that regulate the expression of drug-metabolizing enzymes and nuclear receptors (Song and Wang, 2008; Yu, 2009; Nakajima and Yokoi, 2011; Dluzen and Lazarus, 2015). MiRNAs bind to the mRNA transcripts of target genes by partial sequence complementarity to miRNA response elements (MREs) that are most often located in the 3'-untranslated region (UTR) of target transcripts. Interactions between miRNAs and MREs generally result in either the enhanced degradation of mRNA target transcripts or decreased efficiency of translation.

Previous studies showed that *ALDH5A1* expression is suppressed by the miRNA hsa-miR-29a-3p and that *CYP2E1* expression is modulated by multiple miRNAs (Yu et al., 2015; Wang et al., 2017). Specifically, miR-378a-5p and miR-214-3p bind to the 3'-UTR of *CYP2E1* mRNA transcripts, causing decreased *CYP2E1* protein expression and enzymatic activity (Mohri et al., 2010; Wang et al., 2017), whereas miR-552 suppresses *CYP2E1* protein production by interacting with both the 3'-UTR and the promoter region of *CYP2E1* (Miao et al., 2016). Although a few studies have reported associations between miRNAs and *CYP2E1* and *ALDH5A1* genes, to our knowledge no systematic analysis has been carried out to elucidate the functional roles of miRNAs in the expression of other genes in the catabolic pathway of alcohol, notably other *ADH* and *ALDH* genes expressed in the liver.

In this study, we selected the *ADH* and *ALDH* genes expressed in the human liver and predicted potential miRNA-binding sites located in the 3'-UTRs of these target genes via in silico analyses. Furthermore, we identified hsa-miR-1301-3p as a candidate regulatory miRNA associated with ethanol metabolism. Finally, we tested the regulatory role of hsa-miR1301-3p on the suppression of *ADH6*, *ALDH5A1*, and *ALDH8A1* using a series of in vitro and in vivo experimental approaches. Our results provided new clues to elucidate the epigenetic regulatory mechanisms influencing the expression of ethanol-metabolizing genes, thus adding a new layer of information toward understanding the interindividual variability in ethanol-induced liver injury and ALDs.

Materials and Methods

Chemicals and Reagents. HepG2, Huh7, and 293T cells were obtained from the American Type Culture Collection (Manassas, VA). The hsa-miR-1301-3p mimic and miRNA negative control (NC) were purchased from Ribo Life Science (Shanghai, China). All oligonucleotides and primers used in our study were obtained from Sangon Biotech (Shanghai, China). All reporter gene vectors were produced by Genaray Biotech (Shanghai, China). Rabbit anti-human antibodies against *ADH6*, *ALDH5A1*, and *ALDH8A1* proteins and mouse anti-human antibodies against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were obtained from Abcam (Cambridge, MA). Dual-Luciferase Reporter 1000 Assay System and TRIZOL Reagent were purchased from Promega (Madison, WI). QuantiTect Reverse Transcription kit and Quanti Fast TB Green Real-Time Polymerase Chain Reaction (RT-PCR) kit were obtained from Qiagen (Valencia, CA). NCode miRNA First-Strand cDNA Synthesis kit, radioimmunoprecipitation assay buffer, and LipofectAMINE 2000 reagent were purchased from Life Technologies (Carlsbad, CA). Odyssey Western Blotting Kit was purchased from LI-COR Biosciences (Lincoln, NE). All other reagents were of analytical grade.

In Silico Analyses. Nine *ADH* and 15 *ALDH* genes (Yang et al., 2013) were screened using mRNA data in 98 human liver tissues from The Cancer Genome Atlas (TCGA) data base (<https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga>) to select the alcohol-metabolizing enzymes expressed in human liver. The miRNAs potentially targeting alcohol-metabolizing genes were predicted using the miRTar.human data base (<http://mirtar.mbc.ncu.edu.tw/human/>), and the free energy of miRNA:mRNA duplexes was calculated by RNAhybrid algorithm (<http://bibiserv2.cebitec.uni-bielefeld.de/rnahybrid>), respectively. The correlations between alcohol metabolism genes and miRNAs were calculated by Pearson correlation analysis based on their RNA levels in liver tissues from TCGA data base.

Cell Culture, Transfection, and Ethanol Treatments. HepG2, Huh7, and 293T cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% FBS at 37°C in a humidified 5% CO₂ atmosphere. All cell lines were used at fewer than 10 passages at the time of the study.

The hsa-miR-1301-3p mimic and miRNA NC were transiently transfected into HepG2 and Huh7 cells at the final concentration of 20 nM using LipofectAMINE 2000 reagent. Total RNAs and proteins were extracted at 24 or 48 hours after transfection experiments. In ethanol exposure experiments, HepG2 and Huh7 cells transfected with miRNA mimics were cultured for 24 hours, treated with 50 mM ethanol for another 24 hours, and then harvested to obtain total RNAs and proteins for subsequent analyses. All experiments were carried out at least three times.

Fluorescent-Based RNA Electrophoretic Mobility Shift Assay. Oligonucleotides and primers used in our study were obtained from Sangon Biotech, and their sequences were listed in Supplemental Table 1. The oligonucleotide for hsa-miR-1301-3p was dye-miR-1301-3p, which was synthesized and 5'-modified using DyLight 800 dye. The RNA oligonucleotides corresponding to the MREs of hsa-miR-1301-3p resident in 3'-UTR of *ADH6*, *ALDH5A1*, and *ALDH8A1* were 5'-modified using Cy5.5 dye and designated as dye-*ADH6*, dye-*ALDH5A1*, and dye-*ALDH8A1*, respectively. In addition, 50-fold molar excesses of unlabeled oligonucleotides for negative control were included in competition assays.

Fluorescent-based RNA electrophoretic mobility shift assay (FREMSA) was carried out according to the protocol described in our previous report (Yu et al., 2020). Briefly, 200 fmol dye-miR-1301-3p and cognate dye-*ADH6*, dye-*ALDH5A1*, and dye-*ALDH8A1* oligonucleotides were mixed in basic buffer containing 10 mM HEPES buffer (pH 7.3), 0.5% glycerol, 20 mM KCl, and 10 mM MgCl₂, respectively. The mixtures were incubated for 20 minutes at room temperature and then separated by 10% native PAGE at 4°C. Interaction signals were detected using the Odyssey CLx Infrared Imaging System (LI-COR Biosciences).

Luciferase Reporter Gene Assays. The core 3'-UTRs containing the MREs of hsa-miR-1301-3p located at the 3'-UTRs of *ADH6*, *ALDH5A1*, and *ALDH8A1* were synthesized chemically; subcloned into the pMirGlo system; and designated as ADH6-WT, ALDH5A1-WT, and ALDH8A1-WT, respectively, to create wild-type reporter gene vectors. Furthermore, the mutant sequences that contained mutations in the MREs of hsa-miR-1301-3p in *ADH6*, *ALDH5A1*, and *ALDH8A1*, which obviously increased free energy of miRNA:mRNA duplexes, were synthesized, subcloned into the pMirGlo system, and designated as ADH6-Mut, ALDH5A1-Mut, and ALDH8A1-Mut, respectively. All resultant constructs were sequenced to confirm their authenticity.

293T cells were seeded into 96-well plates at a density of 3×10^4 cells/well and cultured till reaching approximately 80% confluence. Cells were transfected with constructed reporter gene vectors (100 ng/well) together with hsa-miR-1301-3p mimics (final concentration: 50 nM) or miRNA NC (final concentration: 50 nM), using the LipofectAMINE 2000 reagent. Both *Firefly* and *Renilla* luciferase activities were measured at 24 hours after transfection using the Dual-Luciferase Reporter 1000 Assay System, and transfection efficiencies were normalized to *Renilla* luciferase activity. Three independent experiments were conducted in triplicate.

RNA Extraction and Quantitative RT-PCR. The TRIzol Reagent was used to extract total RNAs from HepG2 and Huh7 cells. Reverse transcription reactions of mRNA or miRNA were conducted using QuantiTect Reverse Transcription kit or NCode miRNA First-Strand cDNA Synthesis kit, respectively. The quantitative RT-PCR assays were carried out using Quanti Fast TB Green RT-PCR kit with the LightCycler 480 Detection System (Roche, Basel, Switzerland), and the primer pairs ADH6-F with ADH6-R, ALDH5A1-F with ALDH5A1-R, ALDH8A1-F with ALDH8A1-R, GAPDH-F with GAPDH-R, miR-1301-3p-F with the reverse primer supplemented in the NCode miRNA First-Strand cDNA Synthesis kit, and U6-F with U6-R were designed to detect RNA levels for *ADH6*, *ALDH5A1*, *ALDH8A1*, *GAPDH*, hsa-miR-1301-3p, and the small nuclear RNA U6 control, respectively. The fold changes for *ADH6*, *ALDH5A1*, or *ALDH8A1* mRNA levels were calculated relative to *GAPDH*, whereas the fold change of hsa-miR-1301-3p was relative to snRNA U6 (Jiang et al., 2005). All experiments were carried out at least three times.

Western Blotting. Radioimmunoprecipitation assay buffer was used to extract total proteins from HepG2 or Huh7 cells. Western blotting assays were carried out using the Odyssey Western Blotting Kit and analyzed using the Odyssey CLx Infrared Imaging System. All experiments were carried out at least three times.

Statistical Analyses. One-way ANOVA on ranks test was used to test the differences between subgroups in luciferase assays and RNA or protein experiments, respectively. Data are shown as mean \pm S.D. in the bar graphs, and *P* values of 0.05 were used as the cutoffs for statistical significance.

Results

Selection of miRNAs Potentially Targeting *ADH* and *ALDH* Genes. RNA expression profiles of nine *ADH* and 15 *ALDH* genes (Yang et al., 2013) in human liver tissues were obtained from the TCGA data base. Among these genes, seven *ADH* genes, including *ADH1A*, *ADH1B*, *ADH1C*, *ADH4*, *ADH5*, *ADH6*, and *ADHFE1* (Fig. 1A), and 14 *ALDH* genes, including *ALDH1A1*, *ALDH1A2*, *ALDH1A3*, *ALDH1B1*, *ALDH2*, *ALDH3A1*, *ALDH3A2*, *ALDH3B1*, *ALDH4A1*, *ALDH5A1*, *ALDH6A1*, *ALDH7A1*, *ALDH8A1*, and *ALDH9A1* (Fig. 1B), were observed to be variably expressed in human liver. *ADH1B* and *ALDH2* exhibited the highest expression, whereas *ADHFE1* and *ALDH1A2* were the ones with the lowest expression among the *ADH* and *ALDH* genes. Intriguingly, five *ADH* genes, including *ADH1A*, *ADH1B*, *ADH1C*, *ADH4*, and *ADH6*,




Fig. 1. Expression status of *ADH* (A) and *ALDH* (B) genes in a liver data set obtained from the TCGA data base. RNA levels of nine *ADH* and 15 *ALDH* genes were obtained from 98 liver tissues from the TCGA data base. RPKM, reads per kilobase per million mapped reads.

and four *ALDH* genes, including *ALDH1A1*, *ALDH3A1*, *ALDH1A3*, and *ALDH8A1* presented a wide range of expression levels in liver samples, indicating the individual variability in ethanol metabolism.

We predicted the miRNAs that are potentially able to bind to the 3'-UTRs of seven *ADH* genes and 14 *ALDH* genes using the miRTar.human data base and then calculated the correlations between the expression of potential candidate miRNAs and the expression of their cognate targeting genes based on the liver expression data set from TCGA data base. As shown in Table 1, when the selection criteria were set as: 1) the free energy of binding is smaller than -20.0 kcal/mol and 2) the *R* between the expression of the miRNA and the expression of its target gene is smaller than -0.25 ($r < -0.25$) (Yu et al., 2015c), 11 mature miRNAs were considered as potential epigenetic modulators of *ADH4*, *ADH6*, *ALDH1A3*, *ALDH1B1*, *ALDH3A2*, *ALDH4A1*, *ALDH5A1*, *ALDH8A1*, and *ALDH9A1*, respectively.

Compared with other miRNAs, hsa-miR-1301-3p, hsa-miR-330-5p, and hsa-miR-93-5p showed stronger negative correlations ($r < -0.4$) (Akoglu, 2018) with the *ADH* or *ALDH* genes. Among which, hsa-miR-1301-3p exhibited the highest inverse correlations with mRNAs for *ALDH8A1* ($r = -0.480$), *ADH6* ($r = -0.469$), and *ALDH5A1* ($r = -0.459$) and relatively strong binding affinities with its cognate MRE targets resident in these genes, suggesting its increased regulatory efficiency over the ethanol metabolism process. We then selected hsa-miR-1301-3p and its target genes, including *ADH6*, *ALDH5A1*, and *ALDH8A1*, for focused experiments to test the reliability of miRNA-gene interaction predictions made using bioinformatics (Table 1).

TABLE 1
miRNAs potentially targeting *ADH* and *ALDH* genes

| Gene Symbol | Transcript | miRNA Symbol | Targeting Position | Free Energy (kcal/mol) ^a | Correlation (<i>r</i>) ^b |
|----------------|------------|-----------------|--------------------|-------------------------------------|---------------------------------------|
| <i>ALDH8A1</i> | NM_170771 | hsa-miR-1301-3p | 1911–1932 | –30.6 | –0.480 |
| <i>ADH6</i> | NM_000672 | hsa-miR-1301-3p | 1274–1301 | –28.3 | –0.469 |
| <i>ALDH5A1</i> | NM_001080 | hsa-miR-1301-3p | 1824–1845 | –26.8 | –0.459 |
| <i>ALDH3A2</i> | NM_000382 | hsa-miR-1301-3p | 2681–2702 | –26.8 | –0.353 |
| <i>ALDH5A1</i> | NM_001080 | hsa-miR-149-3p | 2074–2090 | –33.0 | –0.365 |
| <i>ALDH4A1</i> | NM_003748 | hsa-miR-149-3p | 2619–2639 | –28.6 | –0.252 |
| <i>ALDH5A1</i> | NM_001080 | hsa-miR-149-5p | 2512–2533 | –24.4 | –0.365 |
| <i>ADH4</i> | NM_000670 | hsa-miR-185-5p | 1572–1593 | –22.2 | –0.270 |
| <i>ALDH3A2</i> | NM_000382 | hsa-miR-186-3p | 2501–2522 | –20.0 | –0.256 |
| <i>ALDH5A1</i> | NM_001080 | hsa-miR-18a-5p | 2015–2035 | –22.0 | –0.348 |
| <i>ALDH5A1</i> | NM_001080 | hsa-miR-330-5p | 1835–1856 | –26.3 | –0.402 |
| <i>ALDH5A1</i> | NM_001080 | hsa-miR-330-5p | 2008–2029 | –32.5 | –0.402 |
| <i>ALDH4A1</i> | NM_003748 | hsa-miR-330-5p | 2636–2657 | –22.4 | –0.339 |
| <i>ALDH1B1</i> | NM_000692 | hsa-miR-532-3p | 2943–2964 | –23.6 | –0.296 |
| <i>ALDH4A1</i> | NM_003748 | hsa-miR-766-3p | 2393–2414 | –35.2 | –0.285 |
| <i>ALDH4A1</i> | NM_003748 | hsa-miR-766-3p | 3059–3080 | –30.0 | –0.285 |
| <i>ALDH5A1</i> | NM_001080 | hsa-miR-93-3p | 4543–4564 | –22.7 | –0.262 |
| <i>ALDH9A1</i> | NM_000696 | hsa-miR-93-5p | 2314–2335 | –25.2 | –0.454 |
| <i>ALDH1A3</i> | NM_000693 | hsa-miR-93-5p | 2361–2382 | –25.5 | –0.258 |

^aCalculated by the RNAhybrid program.

^bAll $P < 0.05$. The correlations between the expression of potential candidate miRNAs and the RNA levels of their cognate targeting genes based on the liver data set from TCGA data base were calculated by Pearson correlation analysis.

hsa-miR-1301-3p Interacted with *ADH6*, *ALDH5A1*, and *ALDH8A1* Transcripts. FREMSAs were applied to show the direct interactions between hsa-miR-1301-3p and its cognate mRNA targets in vitro (Fig. 2). A strong band formed by dimeric dye-miR-1301-3p was observed in the absence of any targets (Fig. 2, lane 1), which was due to the potential interactions among the dye-miR-1301-3p oligonucleotides (–20.2 kcal/mol, Supplemental Fig. 1). When the dye-*ADH6*, dye-*ALDH5A1*, and dye-*ALDH8A1* oligonucleotide were added, the dye-miR-1301-3p displayed the mobility shift (the top band in Fig. 2, lane 3), and the bands formed by dimeric dye-miR-1301-3p were significantly reduced, respectively, because the mRNA oligonucleotides have the stronger binding ability to dye-miR-1301-3p (–28.3, –26.8, and –30.6 kcal/mol, respectively). The competition assays proved the sequence-specific interactions between hsa-miR-1301-3p and its cognate mRNA targets on *ADH6*, *ALDH5A1*, and *ALDH8A1*. The excess amount of unlabeled oligonucleotides for negative control failed to totally eliminate the densities of the miRNA:RNA complexes formed by dye-miR-1301-3p probe and its MREs in *ADH6* and *ALDH5A1*, respectively (Fig. 2, A and B, lane 4). The nonspecific competitor enhanced the miRNA:RNA complexes formed by dye-miR-1301-3p and dye-*ALDH8A1* oligonucleotides (Fig. 2C, lane 4); however, the reasons for this enhancement remain to be elucidated (Wolfgang et al., 1997; Yu et al., 2018).

hsa-miR-1301-3p Suppressed Luciferase Activity Produced by MRE Sequences Derived from *ADH6*, *ALDH5A1*, and *ALDH8A1* 3'-UTRs. Core sequences containing MREs or mutants within the MREs located at 3'-UTRs (Fig. 3A) of *ADH6*, *ALDH5A1*, or *ALDH8A1* were introduced into luciferase reporter gene vectors and then transfected into 293T cells together with hsa-miR-1301-3p mimics, respectively. As shown in Fig. 3B, hsa-miR-1301-3p mimics dramatically reduced reporter gene activity for constructs containing the MREs derived from the 3'-UTRs of *ADH6* (51.5%, $P < 0.01$), *ALDH5A1* (38.9%, $P < 0.01$), and *ALDH8A1* (37.3%, $P < 0.01$) compared with that in cells treated with the miRNA negative control. Constructs containing mutated MREs for hsa-miR-1301-3p in

ADH6, *ALDH5A1* and *ALDH8A1* (Fig. 3A) were also transfected into 293T cells together with hsa-miR-1301-3p mimics; however, no inhibitory effects were observed. All these evidences proved that hsa-miR-1301-3p was able to bind to its MREs in *ADH6*, *ALDH5A1*, and *ALDH8A1* 3'-UTRs.

In addition, *ALDH5A1* was also predicted to be modulated by another five miRNAs, including hsa-miR-149-3p, hsa-miR-149-5p, hsa-miR-18a-5p, hsa-miR-330-5p, and hsa-miR-93-3p. Among these, hsa-miR-330-5p and hsa-miR-149-3p exhibited the lower free energies of miRNA:mRNA duplexes (less than –30.0 kcal/mol) compared with the other miRNAs, indicating their stronger abilities to bind to the corresponding MREs, respectively. To further validate the reliability of miRNA-gene interaction predictions, hsa-miR-330-5p was selected, and its interaction with *ALDH5A1* 3'-UTR was proved by both FREMSA and luciferase reporter gene assays (Supplemental Fig. 2).

hsa-miR-1301-3p Suppressed Endogenous *ADH6*, *ALDH5A1*, and *ALDH8A1* Production in Hepatic Cells. To investigate the regulatory roles of hsa-miR-1301-3p in the expression of endogenous *ADH6*, *ALDH5A1*, and *ALDH8A1*, we transfected hsa-miR-1301-3p mimics or the miRNA negative control into HepG2 and Huh7 cells and then measured the RNA and protein levels for *ADH6*, *ALDH5A1*, and *ALDH8A1* at 24 hours after transfection. Compared with HepG2 and Huh7 cells transfected with the miRNA negative control, cells transfected with hsa-miR-1301-3p mimics showed elevated levels of hsa-miR-1301-3p (Fig. 4A). Importantly, quantitative RT-PCR assays showed that mRNA levels for *ADH6*, *ALDH5A1*, and *ALDH8A1* were statistically significantly suppressed in HepG2 and Huh7 cells treated with ectopic hsa-miR-1301-3p (Fig. 4B, 18%, 22%, and 33% in HepG2 cells and Fig. 4C, 34%, 37%, and 38% in Huh7 cells, respectively; all $P < 0.05$). Likewise, Western blot assays showed that endogenous *ALDH5A1* and *ALDH8A1* protein levels were reduced in hepatic cells treated with exogenous hsa-miR-1301-3p (Fig. 4D, *ALDH5A1* and *ALDH8A1* protein levels were 45% and 23% in HepG2 cells and 29% and 60% in Huh7 cells, respectively; all $P < 0.05$). Although hsa-miR-1301-3p




Fig. 2. The hsa-miR-1301-3p interacted with *ADH6* (A), *ALDH5A1* (B), and *ALDH8A1* (C) mRNA in vitro. Lanes 1 and 2 indicated the mobility of dye-miR-1301-3p and dye-*ADH6*, dye-*ALDH5A1*, and dye-*ALDH8A1* oligonucleotides, respectively; lane 3 indicated the mobility status of the miRNA:mRNA complex formed by dye-miR-1301-3p oligonucleotides with dye-*ADH6*, dye-*ALDH5A1*, and dye-*ALDH8A1* mRNA oligonucleotides, respectively; lane 4 revealed the mobility shift status of miRNA:mRNA complex in the presence of excess unlabeled nonspecific competitors. NC, nonspecific competitor. The arrow, miRNA:mRNA complex; hollow triangle, monomeric dye-miR-1301-3p; solid triangle, dimeric dye-miR-1301-3p; experiments were carried out at least three times. WT, wild type.

transfection suppressed *ADH6* protein levels in HepG2 cells (23%, $P < 0.05$), we were unable to demonstrate a statistically significant reduction in Huh7 cells, presumably because of reduced expression in this cell line under normal conditions.

hsa-miR-1301-3p Suppressed Ethanol-Dependent Induction of *ADH6*, *ALDH5A1*, and *ALDH8A1* Expression.

It is well-known that *ADH* and *ALDH* genes are inducible by ethanol exposure. We then investigated whether ectopic

hsa-miR-1301-3p can suppress the induction of *ADH6*, *ALDH5A1*, and *ALDH8A1* by ethanol. As shown in Fig. 5A, the cells exposed to 50 mM ethanol resulted in a reduction in the expression of endogenous hsa-miR-1301-3p (52% and 45% in HepG2 and Huh7 cells, respectively; both $P < 0.05$), whereas the transfection of ectopic hsa-miR-1301-3p dramatically elevated the level of hsa-miR-1301-3p even under ethanol exposure.

The levels of *ADH6*, *ALDH5A1*, and *ALDH8A1* mRNA transcripts were elevated upon ethanol exposure (1.19-fold, 1.35-fold, and 1.16-fold in HepG2 cells and 1.18-fold, 1.33-fold, and 1.12-fold in Huh7 cells, respectively; all $P < 0.05$), whereas they were statistically significantly decreased after transfection with hsa-miR-1301-3p mimics with ethanol exposure (decreased by 14%, 42%, and 13% in HepG2 cells and 30%, 11%, and 17% in Huh7 cells, respectively; all $P < 0.05$) (Fig. 5B). Similar regulatory trends were also observed in the protein levels for *ADH6*, *ALDH5A1*, and *ALDH8A1* with the elevations upon ethanol exposure (1.62-fold, 1.27-fold, and 1.40-fold in HepG2 cells and 1.37-fold for *ALDH5A1* and 1.39-fold for *ALDH8A1* in Huh7 cells, respectively; all $P < 0.05$) and the reduction after transfection with hsa-miR-1301-3p mimics and ethanol exposure (reduced by 29%, 22%, and 14% in HepG2 cells and 25% for *ALDH5A1* and 22% for *ALDH8A1* in Huh7 cells, respectively; all $P < 0.05$) (Fig. 5C).

Discussion

ADHs and *CYP2E1* catalyze the conversion of ethanol to acetaldehyde, and *ALDHs* catalyze the transformation of acetaldehyde to acetic acid; regulating the expression of these enzymes appropriately is vital for normal ethanol metabolism (Birley et al., 2009; Hartwell and Kranzler, 2019). The balance between the rates of accumulation and elimination of acetaldehyde (a known mutagen inducing DNA damage) is crucial for the pathologic processes associated with ethanol-induced hepatotoxicity, *ALDs*, and liver cancer (Tan et al., 2017).

Based on the results from a previous study (Yang et al., 2013) and in silico analysis, *ADHs* and *ALDHs* were found to be variably expressed in the human population, consistent with interindividual variability in alcohol and drug metabolism, and variable susceptibility toward *ALDs* among humans. Comprehensive mechanisms involved in the regulation of these enzymes are not fully understood, although it is presumed that genetic variations for *ADH*, *ALDHs*, and *CYP2E1* contribute to interindividual variability in their expression among humans.

In this study, we applied a systematic approach using in silico bioinformatics methods to identify 11 miRNAs that could potentially regulate two *ADH* and seven *ALDH* genes in human liver based on in silico calculations of free energies of miRNAs binding to transcripts and inverse correlations between the expression of these miRNAs and their putative target genes using data from a publicly available data base. Of these 11 candidate regulatory miRNAs, hsa-miR-1301-3p was selected for focused study because the expression of this miRNA in human liver exhibited strong inverse correlations with the expression of several ethanol-metabolizing genes. Our study showed that hsa-miR-1301-3p suppresses the expression of *ADH6*, *ALDH5A1*, and *ALDH8A1* genes in human hepatic cells with or without ethanol exposure using





Fig. 3. The hsa-miR-1301-3p inhibited luciferase reporter gene expression. (A) Free energy analyses of miRNA:mRNA duplex formed by hsa-miR-1301-3p and core or mutated response elements in 3'-UTRs of *ADH6*, *ALDH5A1*, and *ALDH8A1*, respectively, by the RNAhybrid algorithm. (B) Constructs containing the wild-type or mutated sequence of the core 3'-UTRs of *ADH6*, *ALDH5A1*, and *ALDH8A1* genes were transiently transfected into 293T cells, respectively, together with 50 nM hsa-miR-1301-3p mimic or miRNA negative control. Cells were harvested at 24 hours after transfection. Three independent experiments were conducted in triplicate, and data were shown as mean ± S.D. ***P* < 0.01 vs. miRNA negative control.

a series of biochemical assays. These results provide new insight into the epigenetic regulation of ethanol metabolism.

More than 100 algorithms (Henry et al., 2014) have been developed to predict potential mRNA targets for regulation by miRNAs. However, the failure of carefully controlled experiments performed in vitro to confirm predicted miRNA/mRNA target regulatory interactions reveals current limitations of in silico miRNA target predictions made without experimental validation (Thomas et al., 2010; Fan and Kurgan, 2015; Li and Zhang, 2015). Over the past several years we have successfully characterized and confirmed the biochemical functions of many miRNAs in the regulation of drug metabolizing enzymes and transporters (Yu et al., 2015a,b,c, 2018; Jin et al., 2016; Chen et al., 2017; Wang et al., 2017; Zeng et al., 2017; Knox et al., 2018) by integrating a combination of

in silico, in vitro, and in vivo approaches to collect and analyze multiple layers of information.

In this study, in silico analyses predicted that 11 miRNAs, showing a high binding affinity with target sequences and a statistically significantly inverse correlation with their targets at the mRNA level, may potentially modulate two *ADHs* (*ADH4* and *ADH6*) and seven *ALDHs* (*ALDH1A3*, *ALDH1B1*, *ALDH3A2*, *ALDH4A1*, *ALDH5A1*, *ALDH8A1*, and *ALDH9A1*) in the oxidative alcohol-aldehyde-acid metabolic pathway. Furthermore, hsa-miR-1301-3p was selected for focused study because the expression of this miRNA in the human liver exhibited the strongest inverse correlations with the expression of *ADH6*, *ALDH5A1*, and *ALDH8A1* genes. Another important rationale for the selection of hsa-miR-1301-3p is that we recognize the benefits of “killing many birds




Fig. 4. The hsa-miR-1301-3p inhibited endogenous *ADH6*, *ALDH5A1*, and *ALDH8A1* expression in HepG2 cells and Huh7 cells. The hsa-miR-1301-3p mimics or miRNA negative control (both at the final concentration of 20 nM) were transfected into HepG2 and Huh7 cells, respectively. (A) The transfection of hsa-miR-1301-3p mimics dramatically elevated the hsa-miR-1301-3p levels in both HepG2 and Huh7 cells, compared with the transfection of miRNA negative control. Downregulated mRNA levels of *ADH6*, *ALDH5A1*, and *ALDH8A1* were observed after the transfection of hsa-miR-1301-3p mimics in HepG2 (B) or Huh7 cells (C). (D) Protein levels of *ALDH5A1* and *ALDH8A1* were statistically significantly suppressed by exogenous hsa-miR-1301-3p mimics in both HepG2 and Huh7 cells. *ADH6* proteins were statistically significantly decreased by exogenous hsa-miR-1301-3p in HepG2 cells, whereas the detection of *ADH6* proteins failed in Huh7 cells under our experimental conditions. Each assay was carried out in triplicate, and data were shown as mean \pm S.D. The fold changes of miRNA, mRNAs, and proteins induced by exogenous hsa-miR-1301-3p transfection were calculated by defining their levels in the cells transfected with miRNA negative control (miR-NC) as 1. * $P < 0.05$ vs. miRNA negative control. ** $P < 0.01$ vs. miRNA negative control.

with one stone"; in other words, a specific miRNA affecting multiple target genes within the same pathway should have an increased regulatory efficiency over that pathway. This rationale could be physiologically or pharmacologically significant for the major substrates of *ADH6*, *ALDH5A1*, and *ALDH8A1* enzymes, including ethanol, succinic semi-aldehyde, or 2-amino-muconic semialdehyde (Marchitti et al., 2008).

Our FREMSA results showed the direct interactions between hsa-miR-1301-3p and its cognate targets in *ADH6*, *ALDH5A1*, and *ALDH8A1* transcripts in vitro, and further competition assays and reporter gene assays proved the interactions were sequence-specific. Transfection assays showed that ectopic hsa-miR-1301-3p indeed suppressed endogenous *ADH6*, *ALDH5A1*, and *ALDH8A1* production in liver cells. Together, our experimental evidence confirmed our prediction

that hsa-miR-1301-3p interferes with the expression of these enzymes involved in alcohol and aldehyde metabolism.

Although some ADH and ALDH isoforms are inducible by alcohol and aldehyde, the functional significance of most ADH and ALDH enzymes in alcohol and aldehyde metabolism still needs to be elucidated. It was reported that the induction of class I ADH by ethanol involves liver transcriptional factors, such as CCAAT/enhancer-binding proteins (He et al., 2002) and sterol regulatory element-binding protein-1c (He et al., 2004). *ADH6* may be regulated by hormonal changes or by exposure to xenobiotics because of the existence of glucocorticoid response elements (Yasunami et al., 1991) and other regulatory elements, such as CCAAT/enhancer-binding protein α (Humphrey and Kuciasukas, 2006) in its promoter region, but the induction of *ADH6* by alcohol has not been noted previously. Similarly, although some isoforms of human




Fig. 5. The hsa-miR-1301-3p suppressed ethanol-induced *ADH6*, *ALDH5A1*, and *ALDH8A1* expression in HepG2 and Huh7 cells. (A) Ethanol exposure (at the final concentration of 50 mM) resulted in the reduction of endogenous hsa-miR-1301-3p levels in HepG2 and Huh7 cells. $**P < 0.01$ vs. untreated group. $###P < 0.01$ vs. ethanol treatment group transfected with miRNA negative control. $*P < 0.05$ vs. ethanol treatment group transfected with hsa-miR-1301-3p mimics. (B) Exogenous hsa-miR-1301-3p was able to reduce the mRNA levels of *ADH6*, *ALDH5A1*, and *ALDH8A1* that increased by ethanol exposure in HepG2 and Huh7 cells. $*P < 0.05$ vs. control group. $#P < 0.05$; $###P < 0.01$ vs. ethanol treatment group transfected with miRNA negative control. (C) Exogenous hsa-miR-1301-3p was able to reduce the protein levels of *ADH6*, *ALDH5A1*, and *ALDH8A1* that increased by ethanol exposure in HepG2 cells and able to decrease the proteins of *ALDH5A1* and *ALDH8A1* that increased by ethanol exposure in Huh7 cells. $*P < 0.05$; $###P < 0.01$ vs. control group. $#P < 0.05$ vs. ethanol treatment group transfected with miRNA negative control. Each assay was performed in triplicate.

ALDH are inducible, no previous study reported that *ALDH5A1* and *ALDH8A1* are induced by ethanol. It is worth noting that ethanol can stimulate the expression of *ADH6*, *ALDH5A1*, and *ALDH8A1* genes, which is in company with a statistically significant reduction of endogenous hsa-miR-1301-3p levels in HepG2 and Huh7 cells by ethanol exposure, suggesting that the induction of *ADH6*, *ALDH5A1*, and *ALDH8A1* may be mediated by the suppression of hsa-miR-1301-3p. Excessive ectopic hsa-miR-1301-3p could inhibit the induction of *ADH6*, *ALDH5A1*, and *ALDH8A1* in liver cells, further echoing the suppression effect on *ADH6*, *ALDH5A1*, and *ALDH8A1* by hsa-miR-1301-3p.

ADH6, which encodes a class V ADH, is mainly expressed in the liver. Many attempts to purify and characterize the human *ADH6* protein have failed. Although computational studies predicted distinct structural changes existing in *ADH6*, compared with other ADH enzymes (Fagerberg et al., 2014), recombinant human *ADH6* protein expressed in *Escherichia coli* cells showed comparable properties with other ADH isozymes (Chen and Yoshida, 1991). Under our experimental conditions, *ADH6* protein was only detected in HepG2 cells but not in Huh7 cells, indicating that distinctive expression patterns are present in different human hepatic cell lines.

Both ALDH5A1 and ALDH8A1 belong to the superfamily of ALDHs. Besides metabolizing acetaldehyde (Muzio et al., 2012; Davis et al., 2018; Niimi et al., 2018), ALDHs were reported to modulate cell proliferation and differentiation by synthesizing retinoic acid, betaine, and γ -aminobutyric acid (Jackson et al., 2011). Deregulated *ALDH5A1* expression occurred in a variety of cancers (Tian et al., 2017). The knockout of the *ALDH5A1* gene in mice resulted in a significant reduction of glutathione, suggesting that *ALDH5A1* might be associated with mitochondrial function (Sauer et al., 2007). ALDH8A1 was identified as a marker for liver diseases, including cirrhosis and liver cancer (Grinberg et al., 2014), but its functional significance still needs to be elucidated.

Our research strategy is associated with some limitations. First, we only focused on the miRNAs whose expression correlated inversely with the expression of ethanol-metabolizing enzymes in human liver, which is considered to be the classic regulatory mechanism for many miRNAs (i.e., a miRNA inhibits the expression of a target gene by binding to an MRE present in the 3'-UTR of the mRNA transcript). However, accumulating evidences proved that some miRNAs might increase gene expression by interacting with promoters, 5'-UTRs, and the protein-coding regions involving different molecular mechanisms (Ning et al., 2019). Second, we employed a strict threshold (-20 kcal/mol) for the free energy of binding between miRNA:RNA duplexes, which may result in the omission of some regulatory miRNAs that interact with targeting sequences via a non-seed-sequence-dependent manner (Piscioli et al., 1985). Third, it is well-known that one miRNA may target multiple genes, whereas one gene may be targeted by multiple miRNAs. Therefore, the overall effect of the 11 miRNAs, rather than one miRNA, may play an essential regulatory role in the metabolism of ethanol. In the future work, we would validate the regulatory effects of other 10 predicted miRNAs and measure the production of acetaldehyde and acetate, two useful benchmarks to test the activities of ADHs and ALDHs, respectively, to evaluate the overall regulatory roles of multiple miRNAs.

In summary, we predicted 11 regulatory miRNAs that may target *ADH* and *ALDH* genes in human liver based on systematic bioinformatic analyses and in vitro and in vivo experiments. We identified hsa-miR-1301-3p as a new epigenetic factor involved in the regulation of the alcohol-aldehyde-acetate metabolism pathway by suppression of *ADH6*, *ALDH5A1*, and *ALDH8A1*. Our results provide a new clue to interpret the interactions between miRNAs and ethanol metabolism.

Authorship Contributions

Participated in research design: Yu.

Conducted experiments: X. Wang, Y. Zhao, Luo, Xu, X. Li, Jin, Y. Wang.

Performed data analysis: C. Li, Feng, Chen, Hou, Q. Zhao, J. Zhao, Ning, Zheng.

Wrote or contributed to the writing of the manuscript: X. Wang, Y. Zhao, Ning, Yu.

References

Adachi M and Brenner DA (2005) Clinical syndromes of alcoholic liver disease. *Dig Dis* 23:255–263.

Akoglu H (2018) User's guide to correlation coefficients. *Turk J Emerg Med* 18:91–93.

Birley AJ, James MR, Dickson PA, Montgomery GW, Heath AC, Martin NG, and Whitfield JB (2009) ADH single nucleotide polymorphism associations with alcohol metabolism in vivo. *Hum Mol Genet* 18:1533–1542.

Cederbaum AI (2012) Alcohol metabolism. *Clin Liver Dis* 16:667–685.

Chen CS and Yoshida A (1991) Enzymatic properties of the protein encoded by newly cloned human alcohol dehydrogenase ADH6 gene. *Biochem Biophys Res Commun* 181:743–747.

Chen Y, Zeng L, Wang Y, Tolleson WH, Knox B, Chen S, Ren Z, Guo L, Mei N, Qian F, et al. (2017) The expression, induction and pharmacological activity of CYP1A2 are post-transcriptionally regulated by microRNA hsa-miR-132-5p. *Biochem Pharmacol* 145:178–191.

Davis I, Yang Y, Wherritt D, and Liu A (2018) Reassignment of the human aldehyde dehydrogenase ALDH8A1 (ALDH12) to the kynurenine pathway in tryptophan catabolism. *J Biol Chem* 293:9594–9603.

Davison JM, Mellott TJ, Kovacheva VP, and Blusztajn JK (2009) Gestational choline supply regulates methylation of histone H3, expression of histone methyltransferases G9a (Kmt1c) and Suv39h1 (Kmt1a), and DNA methylation of their genes in rat fetal liver and brain. *J Biol Chem* 284:1982–1989.

Dinis-Oliveira RJ (2016) Oxidative and non-oxidative metabolomics of ethanol. *Curr Drug Metab* 17:327–335.

Dluzen DF and Lazarus P (2015) MicroRNA regulation of the major drug-metabolizing enzymes and related transcription factors. *Drug Metab Rev* 47:320–334.

Fagerberg L, Hallström BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Habuka M, Tahmasebpoor S, Danielsson A, Edlund K, et al. (2014) Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. *Mol Cell Proteomics* 13:397–406.

Fan X and Kurgan L (2015) Comprehensive overview and assessment of computational prediction of microRNA targets in animals. *Brief Bioinform* 16:780–794.

Grinberg M, Stöber RM, Edlund K, Rempel E, Godoy P, Reif R, Widera A, Madjar K, Schmidt-Heck W, Marchan R, et al. (2014) Toxicogenomics directory of chemically exposed human hepatocytes. *Arch Toxicol* 88:2261–2287.

Hartwell EE and Kranzler HR (2019) Pharmacogenetics of alcohol use disorder treatments: an update. *Expert Opin Drug Metab Toxicol* 15:553–564.

He L, Ronis MJ, and Badger TM (2002) Ethanol induction of class I alcohol dehydrogenase expression in the rat occurs through alterations in CCAAT/enhancer binding proteins beta and gamma. *J Biol Chem* 277:43572–43577.

He L, Simmen FA, Ronis MJ, and Badger TM (2004) Post-transcriptional regulation of sterol regulatory element-binding protein-1 by ethanol induces class I alcohol dehydrogenase in rat liver. *J Biol Chem* 279:28113–28121.

Henry VJ, Bandrowski AE, Pepin AS, Gonzalez BJ, and Desfeux A (2014) OMICtools: an informative directory for multi-omic data analysis. *Database (Oxford)* 2014: bau069.

Heo MJ, Kim TH, You JS, Blaya D, Sancho-Bru P, and Kim SG (2019) Alcohol dysregulates miR-148a in hepatocytes through FoxO1, facilitating pyroptosis via TXNIP overexpression. *Gut* 68:708–720.

Humphrey JL and Kuciauskas D (2006) Charge transfer enhances two-photon absorption in transition metal porphyrins. *J Am Chem Soc* 128:3902–3903.

Jackson B, Brocker C, Thompson DC, Black W, Vasiliou K, Nebert DW, and Vasiliou V (2011) Update on the aldehyde dehydrogenase gene (ALDH) superfamily. *Hum Genomics* 5:283–303.

Jelski W and Szmittkowski M (2008) Alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) in the cancer diseases. *Clin Chim Acta* 395:1–5.

Jiang J, Lee EJ, Gusev Y, and Schmittgen TD (2005) Real-time expression profiling of microRNA precursors in human cancer cell lines. *Nucleic Acids Res* 33:5394–5403.

Jin Y, Yu D, Tolleson WH, Knox B, Wang Y, Chen S, Ren Z, Deng H, Guo Y, and Ning B (2016) MicroRNA hsa-miR-25-3p suppresses the expression and drug induction of CYP2B6 in human hepatocytes. *Biochem Pharmacol* 113:88–96.

Knox B, Wang Y, Rogers LJ, Xuan J, Yu D, Guan H, Chen J, Shi T, Ning B, and Kadlubar SA (2018) A functional SNP in the 3'-UTR of TAP2 gene interacts with microRNA hsa-miR-1270 to suppress the gene expression. *Environ Mol Mutagen* 59:134–143.

Li Y and Zhang Z (2015) Computational biology in microRNA. *Wiley Interdiscip Rev RNA* 6:435–452.

Liangpunsakul S, Haber P, and McCaughan GW (2016) Alcoholic liver disease in Asia, Europe, and North America. *Gastroenterology* 150:1786–1797.

Marchitti SA, Brocker C, Stagos D, and Vasiliou V (2008) Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. *Expert Opin Drug Metab Toxicol* 4:697–720.

McDaniel K, Herrera L, Zhou T, Francis H, Han Y, Levine P, Lin E, Glaser S, Alpini G, and Meng F (2014) The functional role of microRNAs in alcoholic liver injury. *J Cell Mol Med* 18:197–207.

Meng F, Glaser SS, Francis H, Yang F, Han Y, Stokes A, Staloch D, McCarra J, Liu J, Venter J, et al. (2012) Epigenetic regulation of miR-34a expression in alcoholic liver injury. *Am J Pathol* 181:804–817.

Miao L, Yao H, Li C, Pu M, Yao X, Yang H, Qi X, Ren J, and Wang Y (2016) A dual inhibition: microRNA-552 suppresses both transcription and translation of cytochrome P450 2E1. *Biochim Biophys Acta* 1859:650–662.

Mohri T, Nakajima M, Fukami T, Takamiya M, Aoki Y, and Yokoi T (2010) Human CYP2E1 is regulated by miR-378. *Biochem Pharmacol* 79:1045–1052.

Moss TJ and Wallrath LL (2007) Connections between epigenetic gene silencing and human disease. *Mutat Res* 618:163–174.

Muzio G, Maggiora M, Paiuzzi E, Oraldi M, and Canuto RA (2012) Aldehyde dehydrogenases and cell proliferation. *Free Radic Biol Med* 52:735–746.

Nakajima M and Yokoi T (2011) MicroRNAs from biology to future pharmacotherapy: regulation of cytochrome P450s and nuclear receptors. *Pharmacol Ther* 131:330–337.

Niimi N, Yako H, Takaku S, Kato H, Matsumoto T, Nishito Y, Watabe K, Ogasawara S, Mizukami H, Yagihashi S, et al. (2018) A spontaneously immortalized Schwann cell line from aldose reductase-deficient mice as a useful tool for studying polyol pathway and aldehyde metabolism. *144:710–722.*

- Ning B, Yu D, and Yu AM (2019) Advances and challenges in studying noncoding RNA regulation of drug metabolism and development of RNA therapeutics. *Biochem Pharmacol* **169**:113638.
- Piscioli F, Scappini P, and Luciani L (1985) Aspiration cytology in the staging of urologic cancer. *Cancer* **56**:1173–1180.
- Rodenhiser D and Mann M (2006) Epigenetics and human disease: translating basic biology into clinical applications. *CMAJ* **174**:341–348.
- Sauer SW, Kölker S, Hoffmann GF, Ten Brink HJ, Jakobs C, Gibson KM, and Okun JG (2007) Enzymatic and metabolic evidence for a region specific mitochondrial dysfunction in brains of murine succinic semialdehyde dehydrogenase deficiency (*Aldh5a1*^{-/-} mice). *Neurochem Int* **50**:653–659.
- Song G and Wang L (2008) Transcriptional mechanism for the paired miR-433 and miR-127 genes by nuclear receptors SHP and ERRgamma. *Nucleic Acids Res* **36**:5727–5735.
- Tan SLW, Chadha S, Liu Y, Gabasova E, Perera D, Ahmed K, Constantinou S, Renaudin X, Lee M, Aebersold R, et al. (2017) A class of environmental and endogenous toxins induces BRCA2 haploinsufficiency and genome instability. *Cell* **169**:1105–1118.e15.
- Thomas M, Lieberman J, and Lal A (2010) Desperately seeking microRNA targets. *Nat Struct Mol Biol* **17**:1169–1174.
- Tian X, Han Y, Yu L, Luo B, Hu Z, Li X, Yang Z, Wang X, Huang W, Wang H, et al. (2017) Decreased expression of *ALDH5A1* predicts prognosis in patients with ovarian cancer. *Cancer Biol Ther* **18**:245–251.
- Tilg H and Day CP (2007) Management strategies in alcoholic liver disease. *Nat Clin Pract Gastroenterol Hepatol* **4**:24–34.
- Vasilou V and Nebert DW (2005) Analysis and update of the human aldehyde dehydrogenase (*ALDH*) gene family. *Hum Genomics* **2**:138–143.
- Wang Y, Yu D, Tolleson WH, Yu LR, Green B, Zeng L, Chen Y, Chen S, Ren Z, Guo L, et al. (2017) A systematic evaluation of microRNAs in regulating human hepatic CYP2E1. *Biochem Pharmacol* **138**:174–184.
- Wolfgang CD, Chen BP, Martindale JL, Holbrook NJ, and Hai T (1997) *gadd153/Chop10*, a potential target gene of the transcriptional repressor ATF3. *Mol Cell Biol* **17**:6700–6707.
- Yang L, Price ET, Chang CW, Li Y, Huang Y, Guo LW, Guo Y, Kaput J, Shi L, and Ning B (2013) Gene expression variability in human hepatic drug metabolizing enzymes and transporters. *PLoS One* **8**:e60368.
- Yasunami M, Chen CS, and Yoshida A (1991) A human alcohol dehydrogenase gene (*ADH6*) encoding an additional class of isozyme. *Proc Natl Acad Sci USA* **88**:7610–7614.
- Yu AM (2009) Role of microRNAs in the regulation of drug metabolism and disposition. *Expert Opin Drug Metab Toxicol* **5**:1513–1528.
- Yu D, Chen S, Li D, Knox B, Guo L, and Ning B (2020) FREMSA: a method that provides direct evidence of the interaction between microRNA and mRNA. *Methods Mol Biol* **2102**:557–566.
- Yu D, Green B, Marrone A, Guo Y, Kadlubar S, Lin D, Fuscoe J, Pogribny I, and Ning B (2015a) Suppression of CYP2C9 by microRNA hsa-miR-128-3p in human liver cells and association with hepatocellular carcinoma. *Sci Rep* **5**:8534.
- Yu D, Green B, Tolleson WH, Jin Y, Mei N, Guo Y, Deng H, Pogribny I, and Ning B (2015b) MicroRNA hsa-miR-29a-3p modulates CYP2C19 in human liver cells. *Biochem Pharmacol* **98**:215–223.
- Yu D, Tolleson WH, Knox B, Jin Y, Guo L, Guo Y, Kadlubar SA, and Ning B (2015c) Modulation of *ALDH5A1* and *SLC22A7* by microRNA hsa-miR-29a-3p in human liver cells. *Biochem Pharmacol* **98**:671–680.
- Yu D, Wu L, Gill P, Tolleson WH, Chen S, Sun J, Knox B, Jin Y, Xiao W, Hong H, et al. (2018) Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. *Arch Toxicol* **92**:845–858.
- Zeng L, Chen Y, Wang Y, Yu LR, Knox B, Chen J, Shi T, Chen S, Ren Z, Guo L, et al. (2017) MicroRNA hsa-miR-370-3p suppresses the expression and induction of CYP2D6 by facilitating mRNA degradation. *Biochem Pharmacol* **140**:139–149.

Address correspondence to: Dianke Yu, School of Public Health, Qingdao University, 38 Dengzhou Rd., Qingdao, Shandong 266021, China. E-mail: dianke.yu@qdu.edu.cn
